DOCSLIB.ORG

Top 20 Dysautonomia Drugs Drug Name/Class Helps with Notes Fludrocortisone Increase Blood Volume and Blood Increase Dietary Sodium for (Florinef®) Pressure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Top 20 Dysautonomia Drugs Drug Name/Class Helps with Notes Fludrocortisone Increase Blood Volume and Blood Increase Dietary Sodium for (Florinef®) Pressure Top 20 Dysautonomia Drugs Drug Name/Class Helps with Notes Fludrocortisone Increase blood volume and blood Increase dietary sodium for (Florinef®) pressure. May help in reducing maximum effectiveness. Ideal in plasma NE with long-term use. low doses. (Orthostatic intolerance and orthostatic hypotension.) Midodrine Tightens blood vessels, increases Can cause supine hypertension. (Proamatine®) blood pressure and prevents fainting. (Orthostatic hypotension, POTS and other forms of dysautonomia.) Beta-Blocker Decrease heart rate, blood Known to cause mast cell pressure and adrenaline effects. degranulation. Prevents fainting. (POTS and hyperadrenergic hypertension.) Pyridostigmine Increases blood pressure and (Mestinon®) muscle strength. Reduces breakdown of Acetylcholine in ANS. (Chronic orthostatic hypotension.) IV Saline Increases in blood volume, Symptom improvement is orthostatic tolerance and temporary. Caution should be cognitive function. used when prescribing. (POTS and orthostatic hypotension) Clonidine (Catapres®) or Decreases blood pressure and Methyldopa (Aldomet®) hyperadrenergic responses. Also improves sleep. Decreases sympathetic adrenergic stimulation. www.TheDysautonomiaProject.org A 501 (c) 3 not for profit organization aimed at speeding the time to diagnosis through local education. REGISTRATION # CH42034. A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE (800-435-7352) WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. Ibuprofen Tighten blood vessels. (Motrin®) Blocks inflammatory prostaglandins. Amphetamine (Adderall®) Tighten blood vessels. Increases Use with caution as can be Or Methylphenidate (Ritalin®, alertness. Cognitive function, and addictive. Concerta®) improves brain fog. Reduces appetite. (Chronic orthostatic intolerance) Clonazepam Regulate oscillations of blood Recommended start with low (Klonopin®) flow to heart and vital organs and dose at bedtime. increased sense of calmness. (Multiple system atrophy and chronic orthostatic intolerance.) Alprazolam (Xanax®) Increase sense of calmness. Sedative effect. Droxidopa (Northera®) Increase blood pressure. One of the few FDA approved Also known as L-DOPS (Neurogenic orthostatic drugs for neurogenic. hypotension and other forms of Orthostatic Hypotension. autonomic failure) Tricyclic Antidepressants Improves mood. (E.g. Doxepin) Selective Serotonin Improves mood, reduces anxiety. May cause depression – use Reuptake Inhibitor, caution with teens. (SSRIs) Erythropoietin Increase blood count and blood Difficult to gain coverage through (Procrit®) pressure. insurance. Especially helpful with anemic patients or patients with chronic fatigue. Yohimbine Increase blood pressure (Chronic autonomic failure, multiple system atrophy and automatically mediated syncope.) www.TheDysautonomiaProject.org A 501 (c) 3 not for profit organization aimed at speeding the time to diagnosis through local education. REGISTRATION # CH42034. A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE (800-435-7352) WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. Ivabradine (Corlanor®) Reduces heart rate, angina Useful for patients unable to pectoris, and improves tolerate beta-blockers inappropriate sinus tachycardia (IST). Somatostatin Tighten blood vessels in gut (Octreotide®) Desmopressin Tighten blood vessels and causes (DDAVP®) kidneys to retain water Bethanechol Increase salivation, gut action, (=Urecholine®) and urination. H1 & H2 Antihistamines Tightens blood vessels. May be helpful in patients with Improves inflammation of the coexisting mast cell activation. gut. www.TheDysautonomiaProject.org A 501 (c) 3 not for profit organization aimed at speeding the time to diagnosis through local education. REGISTRATION # CH42034. A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE (800-435-7352) WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. .
Load more

Recommended publications
  • Orthostatic Intolerance V1 4.2.11, F10 Overview V2 6036-7,7038,7040,7042 Orthostatic Intolerance
    NASA-STD-3001 Technical Brief Orthostatic Intolerance V1 4.2.11, F10 Overview V2 6036-7,7038,7040,7042 Orthostatic Intolerance Executive Summary Orthostatic intolerance (OI) is an abnormal response to standing upright caused by an inability to maintain arterial blood pressure and perfuse cerebral tissue. It can result in presyncope and, ultimately, syncope (i.e. loss of consciousness). Specifically in the spaceflight community, OI is a major concern when crewmembers are re-introduced to gravity after landing due to decreased plasma volume and sympathetic nervous system dysfunction. OI must also be considered for standing crew experiencing acceleration loads. A variety of countermeasures can be implemented to reduce the symptoms of and/or completely mitigate OI. Standards Overview NASA-STD-3001 Vol. 1 4.2.11 Fitness-for-Duty Orthostatic Hypotension Standard (with Appendix F.10) All approved countermeasures (fluid loading and compression garments) shall be utilized to mitigate symptoms of orthostatic hypotension (presyncopal/syncopal symptoms) to prevent impacts to performance of critical mission tasks. NASA-STD-3001 Vol. 2 6.3.2.8 Fluid Loading Water Quantity for Earth Entry [V2 6036] 6.3.2.9 Crew recovery Water Quantity [V2 6037] 7.4.1 Physiological Countermeasures Capability [V2 7038] The system shall provide countermeasures to meet crew bone, muscle, sensory-motor, and cardiovascular requirements defined in NASA-STD-3001, Vol. 1. 7.4.3 Physiological Countermeasure Operations [V2 7040] The physiological countermeasure system design shall allow the crew to unstow supplies, perform operations, and stow items within the allotted countermeasure schedule. 7.4.5 Orthostatic Intolerance Countermeasures [V2 7042] The system shall provide countermeasures to mitigate the effects of orthostatic intolerance when transitioning from microgravity to gravity environments.
    [Show full text]
  • Switching from Clonidine Immediate-Release to Guanfacine Extended-Release
    / DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT PSYCHOPHARMACOLOGY Switching from Clonidine Immediate-Release to Guanfacine Extended-Release Dean Elbe PharmD, BCPP1,2,3 s a clinical pharmacy specialist in child and adolescent (Canada) Ltd, 2012b). Clonidine has been used off-label Amental health, I am frequently asked how to switch in children for many years for treatment of insomnia, patients from clonidine immediate-release (IR) to guanfa- ADHD, and disruptive behaviour disorders (Hunt, Capper cine extended-release (XR). This therapeutic switch may be & O’Connell, 1990; Rubinstein; Jaselskis, Cook, Fletcher required when poor adherence to a clonidine IR regimen & Leventhal, 1992; Silver & Licamele, 1994; Palumbo et (typically requiring 3–4 doses daily) is identified, when al., 2008; Efron, Lycett & Sciberras, 2014). A clonidine XR clonidine dose-optimization is limited by sedation, brady- formulation is not available in Canada, but is available in cardia or hypotension, or when coverage situations change. the United States for treatment of ADHD (Concordia Phar- The latter may occur if, for example, new eligibility for a maceuticals, Inc. 2015). government program or a third party-payer occurs. Weight-based dosing guidelines exist for clonidine IR Guanfacine XR, a selective alpha2A agonist, was first mar- (0.003–0.008 mg/kg/day) and guanfacine XR (0.05–0.08 keted in Canada in late 2013 for the treatment of attention mg/kg/day) (Shire Pharma Canada ULC, 2019; Elbe et deficit hyperactivity disorder (ADHD) in children and ado- al., 2018). Based on these guidelines and other literature, lescents (Shire Pharma Canada ULC, 2019).
    [Show full text]
  • Memory Deficits Associated with Clonidine
    Letter to the Editor Letters to the Editor are invited for comment on a topic of current interest or on Table material published in GENERAL HOSPITAL PSYCHIATRY. Letters should be typed doubled spaced and are subject to editing according to space limitations. - Memory Deficits Associated with Attent KnO Clonidine WA Verbal WA Drugs used in the treatment of essential hyperten- Initiation of clonidine therapy (0.1 mg b.i.d.) in WA sion are among the most commonly prescribed. April 1984 resulted in well-controlled hypertension Tactilc Some of these agents have primary effects on neu- without immediately apparent adverse effects. Fulc rotransmitter systems and are centrally active. However, the coincidence of the onset of memory Verba Thus, drugs such as a-methyldopa, propranalol, complaints and the beginning of clonidine treat- 3% ment suggested that clonidine might be respon- List Ll and reserpine have well-established neuropsychia- Fulc tric complications, ranging from depression to cog- sible. si nitive impairments and psychosis [l].Since the use After consultation with the patient's internist, a R of these drugs is widespread and unavoidable, we switch was made to captopril, an angiotensin-con- T must be alert to the possibility that these drugs verting enzyme inhibitor. Before the change we T administered tests of attention, concentration, and contribute to psychologic complaints and symp- -R toms of our patients. verbal skills as well as the Fuld Object-Memory Evaluation, which includes a measure of verbal 'Age-a Clonidine, a presynaptic adrenergic a2agonist, bNonc has become well established as a useful and rela- fluency as well as a selective reminding list learning tively safe therapeutic agent.
    [Show full text]
  • Neurocardiogenic Syncope and Associated Conditions: Insight Into Autonomic Nervous System Dysfunction
    Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2013;41(1):75-83 doi: 10.5543/tkda.2013.44420 75 Neurocardiogenic syncope and associated conditions: insight into autonomic nervous system dysfunction Nörokardiyojenik senkop ve ilişkili durumlar: Otonomik sinir sistemi işlev bozukluğuna bir bakış Antoine Kossaify, M.D., Kamal Kallab, M.D. Department of Syncope and Electrophysiology, ND Secours/USEK University Hospital, Byblos, Lebanon Summary– Neurocardiogenic syncope is known to be asso- Özet– Nörokardiyojenik senkopun mekanizması hala tam ola- ciated with autonomic nervous system dysfunction, although rak aydınlatılamamasına ragmen otonom sinir sistemi işlev the mechanism has not been entirely elucidated. In this study, bozukluğu ile ilişkili olduğu bilinmektedir. Bu yazıda nörokardi- we sought to highlight the pathogenic role of the autonomic yojenik senkop patogenezinde otonom sinir sisteminin rolünü nervous system in neurocardiogenic syncope and to review destekleyen en göze çarpıcı konuları araştırırken, temelinde the associated co-morbidities known to have a dysautonomic otonom sinir sistemi bozukluğunun olduğu bilinen komorbid basis. Herein we discuss migraine, orthostatic hypotension, durumları da gözden geçidik. Bu amaçla otonom sinir siste- postural orthostatic tachycardia syndrome, endothelial dys- minin patogenezdeki rolü ve klinik çıkarımları üzerine odak- function, chronic fatigue syndrome, and carotid sinus hyper- lanarak migren, ortostatik hipotansiyon, postüral ortostatik sensitivity with a focus on the pathogenic role of the autonom- taşikardi sendromu, endotel işlev bozukluğu, kronik yorgunluk ic nervous system and any consecutive clinical implications. sendromu ve karotis sinüs hipersensitivitesi tartışıldı. Tilt testi Other conditions, such as pre-syncopal heart rate acceleration sırasında ortaya çıkabilen senkop öncesi kalp atımlarında hız- and/or instability and pre-syncopal breathing instability, which lanma ve/veya instabilite ve senkop öncesi instabil solunum occur during a tilt test, are discussed in the same perspective.
    [Show full text]
  • Sleep & Dreams & Dsm-5
    PAL Conference - Green River, WY - May 2015 SLEEP & DREAMS & DSM-5: ASSESSMENT AND TREATMENT OF PEDIATRIC INSOMNIA James Peacey, MD PAL Conference Green River, WY Disclosure Statement No relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. I will reference off-label or investigational use of medications in this presentation. PAL Conference - Green River, WY - May 2015 Goals and Objectives Learn how to identify and categorize pediatric insomnia. Increase knowledge of common behavioral and pharmacologic sleep treatments. Increase understanding of sleep issues in particular patient populations (Autism, ADHD, depression and anxiety) and appropriate strategies to optimize treatment. PAL Conference - Green River, WY - May 2015 Sleep Stage Development PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes D. J. Dijk and D. M. Edgar, Regulation of Sleep and Wakefulness, 1999 PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes PAL Conference - Green River, WY - May 2015 Alerting Systems PAL Conference - Green River, WY - May 2015 Normal Sleep Requirements Babcock, Pediatr Clin N Am 58 (2011) 543–554PAL Conference - Green River, WY - May 2015 Percentiles for total sleep duration per 24 hours from infancy to adolescence. Iglowstein I et al. Pediatrics 2003;111:302-307 PAL Conference - Green River, WY - May 2015 ©2003 by American Academy of Pediatrics Insomnia “significant difficulty initiating
    [Show full text]
  • Ehlers-Danlos Syndrome and the Overlap with Orthostatic Intolerance
    10/9/2014 Ehlers‐Danlos Syndrome Ehlers‐Danlos Syndrome and the Overlap with Orthostatic Intolerance • Heterogeneous disorder of connective tissue • Characterized by varying degrees of: October 9, 2014 Skin hyperextensibility Joint hypermobility Cutaneous fragility Peter C. Rowe, MD •Most forms of EDS result from mutations in genes Sunshine Natural Wellbeing Foundation Professor of encoding fibrillar collagens or the collagen‐ Chronic Fatigue and Related Disorders modifying enzymes Johns Hopkins University School of Medicine 1. Royce PM, Steinmann B, Superti‐Furga A. The Ehlers‐Danlos syndrome. In: Connective Tissue and its Heritable Baltimore, USA Disorders. New York: Wiley‐Liss, 1993: 351‐407. 2. de Paepe A, Malfait F. The Ehlers‐Danlos syndrome, a disorder with many faces. Clin Genetics 2012;82:1‐11. Presenter Disclosure Information Ehlers‐Danlos Syndrome Peter C. Rowe, MD • Prevalence unknown, estimated at 1:5000 •Because fibrillar collagen provides strength and structure to essentially all tissues and organs, EDS •No relationships to disclose has widespread clinical manifestations •Early varicose veins, easy bruising •Easy fatigability and widespread pain common Royce PM, Steinmann B, Superti‐Furga A. The Ehlers‐Danlos syndrome. In: Connective Tissue and its Heritable Disorders. New York: Wiley‐Liss, 1993: 351‐407. EDS, JH, and Orthostatic Intolerance Classification of EDS Beighton P, et al. Am J Med Genetics 1998;77:31‐7. Overview of Ehlers‐Danlos Syndrome Classical Illustrative case (formerly EDS I and II) Orthostatic intolerance in EDS and JH Hypermobility (formerly EDS III) Challenges Vascular (formerly EDS IV) Kyphoscoliosis Arthrochalasia 3 generations with Classical EDS. Note hemosiderin deposition in knees and Dermatosparaxis shins, varicose vein stripping on R 1 10/9/2014 de Paepe A, Malfait F.
    [Show full text]
  • GP GUIDE to Pots (Postural Tachycardia Syndrome)
    GP GUIDE TO PoTS (Postural Tachycardia Syndrome) 1 WHAT IS PoTS? PoTS was characterised in 1993, but previously existed under various other names including irritable heart, soldier’s heart and idiopathic orthostatic intolerance. It is a heterogeneous group of disorders sharing similar characteristics. On assuming upright posture, there is an excessive increase in heart rate associated with symptoms of orthostatic intolerance and sympathetic over-activity. There is brain hypoperfusion, usually in the absence of hypotension. When humans adopt upright posture, approximately 500ml of blood drops into the abdominal cavity and limbs. A normal autonomic nervous system responds with immediate peripheral vasoconstriction and an increase in heart rate of up to 20bpm. In POTS, it is considered that vasoconstriction is inadequate, resulting in pooling of blood, relative hypovolaemia and reduced venous return to the heart. Heart rate, inotropic status and, in some patients, catecholamine levels increase further to compensate. Dizziness and syncope can occur in the presence of normal BP; in fact some patients with PoTS have a hypertensive response to standing. HOW COMMON IS PoTS? The incidence in the UK is unknown. However, it is probably under-diagnosed due to lack of awareness and non-specific symptomatology. It is five times more common in women and tends to affect people age 15 to 50. 2 SYMPTOMS OF PoTS Dizziness GI upset Syncope / pre-syncope Sweating Orthostatic headache Nausea Fatigue Insomnia Poor memory Weakness Poor concentration Visual greying or blurring Sense of anxiety Acrocyanosis (purplish hands/feet) Exercise intolerance Palpitations (tachycardia / ectopics) Tremulousness Neck/shoulder pain (muscle ischaemia) Patients may have some or all of the above symptoms.
    [Show full text]
  • What Is the Autonomic Nervous System?
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.suppl_3.iii31 on 21 August 2003. Downloaded from AUTONOMIC DISEASES: CLINICAL FEATURES AND LABORATORY EVALUATION *iii31 Christopher J Mathias J Neurol Neurosurg Psychiatry 2003;74(Suppl III):iii31–iii41 he autonomic nervous system has a craniosacral parasympathetic and a thoracolumbar sym- pathetic pathway (fig 1) and supplies every organ in the body. It influences localised organ Tfunction and also integrated processes that control vital functions such as arterial blood pres- sure and body temperature. There are specific neurotransmitters in each system that influence ganglionic and post-ganglionic function (fig 2). The symptoms and signs of autonomic disease cover a wide spectrum (table 1) that vary depending upon the aetiology (tables 2 and 3). In some they are localised (table 4). Autonomic dis- ease can result in underactivity or overactivity. Sympathetic adrenergic failure causes orthostatic (postural) hypotension and in the male ejaculatory failure, while sympathetic cholinergic failure results in anhidrosis; parasympathetic failure causes dilated pupils, a fixed heart rate, a sluggish urinary bladder, an atonic large bowel and, in the male, erectile failure. With autonomic hyperac- tivity, the reverse occurs. In some disorders, particularly in neurally mediated syncope, there may be a combination of effects, with bradycardia caused by parasympathetic activity and hypotension resulting from withdrawal of sympathetic activity. The history is of particular importance in the consideration and recognition of autonomic disease, and in separating dysfunction that may result from non-autonomic disorders. CLINICAL FEATURES c copyright. General aspects Autonomic disease may present at any age group; at birth in familial dysautonomia (Riley-Day syndrome), in teenage years in vasovagal syncope, and between the ages of 30–50 years in familial amyloid polyneuropathy (FAP).
    [Show full text]
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review
    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
    [Show full text]
  • 39 Voiding Dysfunction in Patients with Dysautonomia
    39 Shridharani A1, Guralnick M1, Barboi A1, Jaradeh S1, Prieto T1, Yellick M1, O'Connor R C1 1. Medical College of Wisconsin VOIDING DYSFUNCTION IN PATIENTS WITH DYSAUTONOMIA Hypothesis / aims of study Dysautonomia, or autonomic dysfunction, is a primary neurologic condition resulting from failure of the sympathetic or parasympathetic nervous systems. The disorder has a myriad of clinical presentations including dysregulation of body temperature, orthostatic intolerance, gastrointestinal motility disorders and chronic pain syndromes. Urologically, while sexual dysfunction has been recognized as part of the autonomic dysfunction spectrum, voiding symptoms have been inadequately characterized. We present the chief urologic complaints, results of urodynamic studies and treatments of patients with a known history of dysautonomia referred to our neuro-urology clinic. Study design, materials and methods Retrospective chart review was performed on all patients seen between 2003 and 2008 in the neuro-urology clinic for voiding dysfunction with the concomitant diagnosis of dysautonomia. Patients with other neurologic diagnoses, such a multiple sclerosis or a history of spinal surgery, were excluded from the analysis. All patients underwent focused history and physical examination as well as video urodynamic studies. Upper tract imaging by renal ultrasound or computerized tomography of the abdomen/pelvis was performed on select patients. Treatment modalities that subjectively and objectively improved the patient’s symptoms were recorded. Objective improvements were measured via post void residual bladder volume, uroflowmetry and/or urodynamic studies. Results Of 443 patients with the diagnosis of dysautonomia, 37 (8%) were referred for evaluation of voiding dysfunction. Mean age was 47 years (range 12 - 80) and 31/37 (84%) patients were female.
    [Show full text]
  • Data Sheet SURMONTIL Trimipramine (As Maleate) 25 Mg Tablets and 50 Mg Capsules
    Data Sheet SURMONTIL trimipramine (as maleate) 25 mg tablets and 50 mg capsules Presentation SURMONTIL tablets are compression coated, white or cream, circular, biconvex, containing the equivalent of 25mg trimipramine (as maleate) with a diameter of about 8.0mm. The face is indented with the name and strength, reverse plain. SURMONTIL capsules are opaque white with opaque green cap, printed SU50, each containing the equivalent of 50mg trimipramine (as maleate). Uses Actions SURMONTIL has a potent anti-depressant action similar to that of other tricyclic anti-depressants. The mechanism of action is not fully understood but it is thought to be via inhibition of neuronal re- uptake of noradrenalin, thereby increasing availability. SURMONTIL also possesses a pronounced sedative action. Pharmacokinetics SURMONTIL is readily absorbed after oral administration, reaching a mean peak plasma level after 3 hours. High first pass hepatic clearance results in a mean bioavailability of about 41% of the oral dose, and trimipramine is extensively protein bound in plasma. Elimination half-life is 24 hours. Metabolism is in the liver to its major metabolite, desmethyltrimipramine, which is excreted mainly in the urine. Indications SURMONTIL is indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days. Dosage and Administration Adults Mild/Moderate Depression in General Practice: The recommended dosage is 50-75 mg orally given two hours before bedtime, the larger dose (75 mg) being preferable for those patients with more marked sleep disturbance.
    [Show full text]
  • Neuromuscular Weakness in The
    Neuromuscular Disorders in the Intensive Care Unit -when and how M. S. Damian, Addenbrookes Hospital, Cambridge Background to this talk? • Neuromuscular admissions to the ICU are increasing • The incidence of individual conditions is not clear • The true outcomes of these patients are unclear • Mortality rates in patients treated with Myasthenia and Guillain Barre Syndrome have not significantly improved in the last 20 years, neither have treatments [Damian MS, Howard R, Int Care Med 2013] • Bad medicine is expensive (Example: An MG case with recurrent crises. 1 year pre-Rituximab: £39,810 costs incl. 14d ICU stay 1 year on Rituximab: ca. £8,000 total costs, no ICU stay M. S. Damian, Addenbrookes Hospital, Cambridge Which neuromuscular symptoms may require treatment in the ICU? • Severe respiratory weakness • Bulbar weakness and aspiration • Cardiomyopathy and heart failure • Arrhythmia • Dysautonomia • Acute rhabdomyolysis and renal failure M. S. Damian, Addenbrookes Hospital, Cambridge 3 main groups of patients with neuromuscular disease may require treatment in the ICU I. Patients with severe new onset of neuromuscular disease II. Patients with pre-existing chronic neuromuscular conditions who develop acute complications III. Patients whose neuromuscular disorder arises in the ICU M. S. Damian, Addenbrookes Hospital, Cambridge Severe new onset neuromuscular disease in the ICU • Guillain Barre Syndrome • Severe acute neuropathy • Acute flaccid paralysis syndrome (WNV, enterovirus 71- mostly with encephalitis) • Myasthenic crisis and
    [Show full text]